Renal cell cancer (RCC) has become a prototype example of the extensive intratumor heterogeneity and clonal evolution of human
cancers. However, there is little direct evidence on how the genetic heterogeneity impacts on
drug response profiles of the
cancer cells. Our goal was to determine how genomic clonal evolution impacts
drug responses. Finding from our study could help to define the challenge that clonal evolution poses on
cancer therapy. We established multiple patient-derived cells (PDCs) from different
tumor regions of four RCC patients, verified their clonal relationship to each other and to the uncultured
tumor tissue by genome sequencing. Furthermore, comprehensive
drug-sensitivity testing with 460 oncological drugs was performed on all PDC clones. The PDCs retained many
cancer-specific copy number alterations and mutations in driver genes such as VHL, PBRM1, PIK3C2A, KMD5C and TSC2 genes. The
drug testing highlighted vulnerability in the PDCs toward approved RCC drugs, such as the mTOR-inhibitor
temsirolimus, but also novel sensitivities were uncovered. The individual PDC clones from different
tumor regions in a patient showed distinct
drug-response profiles, suggesting that genomic heterogeneity contributes to the variability in
drug responses. Studies of multiple PDCs from a patient with
cancer are informative for elucidating
cancer heterogeneity and for the determination on how the genomic evolution is manifested in
cancer drug responsiveness. This approach could facilitate tailoring of drugs and
drug combinations to individual patients.